Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.72 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1334.98 | 6020.47 | — | 462.70 | 433.40 | 356.75 | 176.54 | 244.53 | 3959.64 | 124.87 | 214.34 | 1495.61 | 439.18 |
| — | +1587.6% | — | +89.2% | -89.1% | +185.7% | -17.6% | -83.7% | +801.6% | -61.6% | -73.5% | -22.6% | -80.8% | |
| P/B Ratio | 3.80 | 3.43 | 2.87 | 2.06 | 1.71 | 2.24 | 2.87 | 3.00 | 2.95 | 4.81 | 5.27 | 5.78 | 5.61 |
| — | +52.6% | +0.2% | -31.4% | -41.8% | -53.3% | -45.6% | -48.0% | -47.5% | -25.3% | +38.1% | +67.3% | +40.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Celldex Therapeutics, Inc.'s operating margin was -116249.3% in Q4 2025, down 111481.1 pp YoY. The trailing four-quarter average of -44674.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 230.1% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 100.0% | 30.3% | 100.0% | 68.1% | -396.8% | -636.5% | 49.4% | -9695.5% | -2671.3% |
| — | +230.1% | — | +46.9% | +125.2% | +104.8% | +102.3% | +100.7% | +85.1% | +51.8% | +101.0% | +23.2% | +72.5% | |
| Operating Margin | -19160.0% | -116249.3% | — | -8747.5% | -9027.2% | -4768.3% | -1633.5% | -1854.2% | -26030.8% | -1152.9% | -2718.5% | -12389.9% | -3357.9% |
| — | -2338.0% | — | -371.8% | +65.3% | -313.6% | +39.9% | +85.0% | -675.2% | +33.3% | +60.1% | +44.5% | +74.9% | |
| Net Margin | -17253.3% | -108480.0% | — | -7753.4% | -7740.4% | -4007.8% | -1320.0% | -1434.8% | -21030.8% | -1048.3% | -2522.1% | -11381.3% | -3036.3% |
| — | -2606.7% | — | -440.4% | +63.2% | -282.3% | +47.7% | +87.4% | -592.6% | +36.2% | +61.7% | +48.5% | +77.1% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -40.6% | -14.5% | -10.7% | -8.3% | -7.4% | -6.1% | -5.3% | -4.3% | -5.2% | -12.8% | -14.6% | -10.5% | -9.3% |
| — | -135.3% | -103.1% | -92.1% | -43.4% | +52.1% | +63.9% | +58.7% | +44.6% | -62.5% | -93.6% | -11.4% | -65.6% | |
| ROA | -37.6% | -13.2% | -10.0% | -7.9% | -7.0% | -5.8% | -5.0% | -4.2% | -4.9% | -11.6% | -13.2% | -9.8% | -8.7% |
| — | -126.7% | -98.1% | -89.1% | -42.8% | +49.8% | +61.8% | +57.2% | +43.3% | -58.3% | -90.3% | -12.3% | -63.4% | |
| ROIC | -35.2% | -12.3% | -9.2% | -7.2% | -6.7% | -5.7% | -5.1% | -4.6% | -5.4% | -11.4% | -12.9% | -9.9% | -8.8% |
| — | -115.4% | -79.5% | -56.0% | -22.9% | +50.1% | +60.2% | +53.0% | +38.4% | -72.4% | -107.8% | -29.4% | -91.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 44.6% YoY to 10.49x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -13.2% | +11.5% | +57.8% | +93.4% | -13.8% | -65.9% | -75.0% | -79.1% | -52.1% | +9.8% | +6.8% | +81.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.49 | 10.49 | 13.01 | 19.67 | 21.67 | 18.91 | 24.27 | 29.36 | 31.77 | 13.87 | 8.84 | 16.93 | 19.03 |
| — | -44.6% | -46.4% | -33.0% | -31.8% | +36.4% | +174.7% | +73.5% | +67.0% | -18.8% | -57.0% | +37.8% | -29.1% | |
| Quick Ratio | 10.49 | 10.49 | 13.01 | 19.67 | 21.67 | 18.91 | 24.27 | 29.36 | 31.77 | 13.87 | 8.84 | 16.93 | 19.03 |
| — | -44.6% | -46.4% | -33.0% | -31.8% | +36.4% | +174.7% | +73.5% | +67.0% | -18.8% | -57.0% | +37.8% | -29.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -15.31 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCelldex Therapeutics, Inc.'s current P/E is -7.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Celldex Therapeutics, Inc.'s current operating margin is -19160.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Celldex Therapeutics, Inc.'s business trajectory between earnings reports.